Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
Healthcare
$0.61 -1.46%
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
52W Low $1.61High $6.88
Volume 2.90M
Average 7.64M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$49.14M
FY 2025 · Annual
Investing Cash Flow
-$93.31M
FY 2025 · Annual
Financing Cash Flow
$129.61M
FY 2025 · Annual
+647.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Depreciation & Amortization | 1.62M | 1.9M | 1.89M | 1.75M | (1.4M) |
| Deferred Income Tax | 50.58M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.03M | 5.33M | 6.12M | 8.56M | 8.37M |
| Change in Working Capital | 6.25M | (1.26M) | (2.91M) | (4.14M) | 9.18M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (194K) | 2.52M | 708K | (1.84M) | (664K) |
| Other Working Capital | 6.44M | (3.78M) | (3.62M) | (2.3M) | 9.84M |
| Other Non-Cash Items | 41K | (871K) | 5.97M | (1.65M) | 1.2M |
| Operating Cash Flow | (19.67M) | (34.13M) | (40.62M) | (44.86M) | (49.14M) |
| Capital Expenditures | (1.57M) | (212K) | (30K) | (44K) | (25K) |
| Acquisitions (Net) | 116K | 176K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (200.12M) | (155.42M) | (88.16M) | (194.56M) |
| Sales of Investments | 0 | 48.96M | 182.41M | 134.97M | 101.28M |
| Other Investing Activities | (318K) | (150.99K) | 27K | 0 | 0 |
| Investing Cash Flow | (1.77M) | (151.2M) | 26.97M | 46.77M | (93.31M) |
| Debt Repayment | — | — | — | 0 | 0 |
| Common Stock Issued | 128.27M | 76.24M | 3.09M | 18.11M | 130.64M |
| Common Stock Repurchased | 0 | 0 | (159) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (281K) | (480K) | (159K) | (775K) | (1.03M) |
| Financing Cash Flow | 118.61M | 75.76M | 2.94M | 17.34M | 129.61M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 97.18M | (109.57M) | (10.72M) | 19.26M | (12.84M) |
| Free Cash Flow | (21.23M) | (34.34M) | (40.65M) | (44.9M) | (49.17M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$66.5M
+ D&A-$1.4M
+ Stock-Based Comp$8.4M
+ Deferred Tax$0
+ Working Capital$9.2M
+ Other Non-Cash$1.2M
= Operating Cash Flow-$49.1M
- Capex-$25.0K
= Free Cash Flow-$49.2M
Analysis
FY2025 free cash flow is -$49.2M. FCF conversion is 73.9% of net income. Operating cash flow was -$49.1M, with capex of -$25.0K. The largest bridge item is Working Capital at $9.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 |
Does CMPX generate free cash flow?
Compass Therapeutics, Inc. (CMPX) generated -$49.17M of free cash flow in fiscal 2025.
How much operating cash flow does CMPX produce?
Operating cash flow was -$49.14M, before capital expenditures of $25,000.00.
Continue the stock analysis
Jump to another research area for this company.